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Introduction
Acute idiopathic sensorineural hearing loss may be de-
fined as a hearing loss of 30 dB or more, over at least 3 
contiguous audiometric frequencies, that develops over 
72 hours or less. This is a medical emergency and vari-
ous possible causal factors have been postulated. The 
optimal treatment modality is not known either, and this 
is reflected in the large number of publications suggest-
ing the ‘best’ treatment modality. Some cases will im-
prove spontaneously. Trans-tympanic steroid injections 
are the most recent form of treatment being studied and 
may provide hope for these patients, however due to the 
rarity and the unpredictable natural history of the dis-
order it is difficult to design and conduct a study on 
this condition in order to show a statistically significant 
difference.
Material and methods
A postal questionnaire was sent to consultant members of 
the British Association of otolaryngology-head & neck 
Surgery (BAo-hnS). This was accompanied by a case 
scenario of a patient with acute, unilateral, idiopathic loss 
(Appendix 1).
Results
A total of 540 questionnaires were posted by a single 
mailshot. There were 266 replies (49.2% response rate). 
Some of the questionnaires were not fully completed and 
this is reflected in the totals of the individual results. The 
percentage figures given for a choice are those for com-
pleted questions only.
in reply to the question regarding the admission of this pa-
tient with unilateral, acute, idiopathic sensorineural hearing 
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loss, 153 (59.1%) stated they would admit him. of those who 
would not admit the patient, only one would also not arrange a 
follow-up in the clinic. The remainder would arrange a follow-
up at intervals ranging from 2 days to 6 months with a median 
value of 14 days. of those who would admit the patient, only 
29.7% (44/153) had a written protocol for patient manage-
ment. of the total (239) who would treat the patient, whether 
they admitted him/her or not, 23.8% (57/239) had a written 
protocol. The proposed in-patient stay varied between one and 
10 days, mean 3.7 days (Standard deviation (Sd) 1.9).
The patient would be reviewed in the clinic after a median 
of 14 days following discharge from hospital. Two con-
sultants said they would not follow the patient up after an 
in-patient stay.
nearly all, 93.2% (248/266), would prescribe some form 
of treatment. of these, 96% (238/248) would prescribe 
oral steroids alone or in combination with other drugs, 
and 3 consultants (1.2%) in this group would give steroids 
intra-tympanically. The duration of the steroid course pre-
scribed varied from 2 to 30 days, (median 7 days).
low molecular weight dextran would be prescribed by 58 
consultants (23.4%), 96 (38.7%) carbogen, 75 (30.2%) 
betahistine and 45 (18.1%) aspirin. The duration of carbo-
gen prescribed varied from 1 to 14 days (median 3 days). 
Fifteen  consultants  (6.0%)  suggested  antiviral  agents, 
such as acyclovir. Peripheral vasodilators or calcium an-
tagonists were used by 18 consultants (7.3%). less com-
monly used treatments were hyperbaric oxygen (hBo) 
which was prescribed by 5 consultants (2.0%), heparin 
by 4 consultants (1.6%) while 3 (1.2%) would give anti-
biotics. other modalities of treatment suggested, included 
methotrexate, practolol, dyazide, tranquillisers and plas-
ma exchange.
of those consultants who would treat the patient, 30.8% 
(76/247) would use only one form of treatment. The re-
mainder would prescribe two or more drugs. The number 
of combinations of drugs and how frequently they would 
be prescribed are outlined in Figure 1. Full details of the 
exact combinations used are shown in Figure 2.
The question regarding whether they thought their treat-
ment would improve the patient’s prognosis was answered 
by 253 consultants. A modest number, 68 (26.9%) stated 
that they thought the prognosis would be improved by 
medical treatment and 41 (16.2%) stated that they thought 
that medical treatment would not improve recovery. The 
majority of 144 consultants (56.9%) were unsure about 
the efficacy of medical treatment.
of the 251 consultants who replied to the question on tim-
ing of the second audiogram after presentation, 140 out of 
251 (55.8%) stated that they would repeat it after one or 
two days. A further 71 (28.3%) would repeat the audio-
gram within one week.
The consultants who would admit the patient (133) were 
asked about the investigations that they would undertake. 
These are outlined in Figure 3.
Fig. 1. Number of methods of treatment administered by each Consultant.
Fig. 2. Treatment combinations in order of frequency.
Fig. 3. Investigations performed by each consultant whilst patient is hos-
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Discussion
Acute idiopathic sensorineural hearing loss is a rare occur-
rence. The exact incidence of acute sensorineural hearing 
loss is not known, but is estimated to be between 5 and 20 
per 100,000 persons/year and varies with age 1. This condi-
tion may be extremely distressing for the patients affected 
as it has a significant impact on their ability to interact so-
cially and they may be concerned that there is some serious 
underlying pathological condition. various causes, includ-
ing viral 2-5, vascular 6 or autoimmune conditions 7, have 
been postulated. As yet, no single causal agent has been 
identified and the aetiology may be multifactorial.
many different treatment regimens have been suggested. 
These included the use of steroids 8 (which may be given 
intra-tympanically)  9  10,  low  molecular  weight  dextran  11, 
carbogen 12, hyperbaric oxygen 13, ldl apheresis 14, acyclo-
vir 15 and even stellate ganglion block 16. There is little con-
vincing evidence that any one treatment produces any im-
provement in the audiometric results 17. it is, however, quite 
difficult, for various reasons, to design and conduct a study 
on this condition, in order to show a statistically, and more 
importantly, a clinically significant difference. There are 
many reasons for this. First of all, the condition is relatively 
uncommon, and recruitment of an adequate number of pa-
tients, to allow a double-blind clinical trial to be conducted, 
would be difficult. The second problem is that the disorder 
is most likely not the result of a single disease process. A 
drug may help one of the causes, but not another, thus re-
sulting in confusing outcomes. A third difficulty is that of 
spontaneous recovery of hearing. A spontaneous recovery 
rate of approximately 60% has been quoted 18, although the 
ranges in the literature vary considerably (32-89%) 19 20.
The prognosis is not predictable. variables which may 
worsen the prognosis, include increasing age of the pa-
tient, number of days before presentation, a more severe 
initial mean hearing loss and the presence of vertigo 21 22. 
A better prognosis may be associated with early hearing 
improvement 23 and prompt administration of corticoster-
oids 8 24 but this is controversial 25. These factors may need 
to be taken into account when analysing results.
There is no general agreement regarding the definition of 
what constitutes acute, idiopathic sensorineural hearing 
loss. There is no consensus regarding the time period of 
evolution (in order to classify as acute) or which investi-
gations need to be performed (in order to classify as idio-
pathic). one definition in the literature is “a loss of 30 dB 
at three contiguous frequencies within three days” 8.
The results of our study show that 60 percent of consult-
ants would admit a patient with this condition to hospi-
tal, with an average in-patient stay of 3.7 days. nearly all 
(98.0%) would prescribe steroids, for a mean course of 
9.1 days. A further 3 consultants (1.2%) would prescribe 
intra-tympanic steroids.
dextran 40 is still available, but has recently not been pre-
scribed due to concerns raised regarding its safety 26, especial-
ly in elderly patients. low molecular weight dextran increases 
plasma viscosity, and should be used with caution in patients 
with heart disorders or renal impairment, since pulmonary 27 
or renal failure 28 may result and deaths have been reported 29. 
whilst this infusion is being administered, the patient’s urine 
and haematocrit should be closely monitored.
A magnetic resonance imaging (mri) scan of the internal 
auditory meatus should be performed in all cases 30, even 
if their hearing loss improves 31 32.
A study of 67 patients with acute sensorineural hearing 
loss, by Nageris and Popovtzer found 24 patients had an 
acoustic neuroma; of these 4 (16.7%) recovered hearing 
after 1 month 33. rarely, a vestibular schwannoma may 
present in this manner 34-37. Further investigations may help 
to identify factors which contribute to the hearing loss.
The united States national institute of health is currently 
running a multi-centre randomised controlled trial 38 to 
compare the efficacy of oral prednisolone and intra-tym-
panic methyl-prednisolone for the treatment of moderate 
to severe sensorineural hearing loss. details of this study 
can be found on the following web site: www.clinicaltri-
als.gov/ct/show/nCT00097448.
Conclusions
it is interesting that so many consultants admit patients with 
this condition, despite the lack of reliable evidence that any 
one treatment is of proven benefit. one may assume that this 
is due to our wish to do everything possible for the patient 
and also, in part, because of the fear of litigation.
The vast majority (89%) of respondents would treat acute 
unilateral sensorineural hearing loss with steroids. A fur-
ther 1.2% would give intra-tympanic steroid injections. 
This practice may change pending the results of the unit-
ed States national institute of health Study.
All patients should have an mri scan, even if they have 
recovered from the hearing loss.
From our questionnaire, it can be seen that the treatment 
of this condition remains controversial. it is important that 
each patient should be thoroughly investigated and any 
treatable cause identified.
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Appendix 1
A 60-year-old male presents with an acute, right-sided hearing loss. This had occurred less than 24 hours previously and was not associated with any other 
otological or neurological symptoms. The patient is otherwise medically fit and well and has never had any problems with his ears in the past. Pure tone 
audiometry shows a flat, 60 dB sensorineural hearing loss on the right. Hearing in the left ear is 20 dB. How would you manage him?
1. Would you admit him to hospital? Yes/No
2. If you would not admit him, when would you follow him up in your clinic?
3. Do you have a standard written protocol for these patients?
4. What treatment would you give this man? (Please tick)
5. If applicable, how many days would you
     a) Treat him with steroids? .......days
     b) Treat him with Carbogen? ......days
     c) Keep him in hospital? ......days
6. Do you think your management will improve his prognosis? Yes/No/Don’t know
7. How frequently would you repeat the audiogram?
    Daily / Every other day / Every .......days / Other (Please state).
8.While he is in hospital, which of the following investigations would you perform? (Please tick).
9. After discharge from hospital when would you review him in clinic?
    .......days /........weeks
Steroids Dextran 40 Carbogen
Betahistine Heparin Antibiotics
Aspirin Hyperbaric oxygen Other (Please state)
FBC Clotting studies
ESR Urinalysis
Plasma viscosity Viral antibody screen
Lipids Syphilis serology
Glucose CXR
Creatinine CT temporal bone
TFT’s MRI temporal bone
Other tests
(Please state)